Cerebrospinal Fluid Interleukin-6 in Central Nervous System Inflammatory Diseases

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wullschleger, Alexandre ^a   Kapina, Viktoria ^a   Molnarfi, Nicolas ^a,b   Courvoisier, Delphine S ^a,c   Seebach, Jörg D ^d   Santiago Raber, Marie Laure ^b   Hochstrasser, Denis F ^a   Lalive, Patrice H ^a,b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d University Hospital and Medical Faculty of Geneva   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; ENCEPHALITIS; ENCEPHALOMYELITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IDIOPATHIC DISEASE; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PROTEIN DETERMINATION; RANK SUM TEST; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS;

ADULT; AGED; BIOLOGICAL MARKERS; DEMYELINATING DISEASES; DIAGNOSIS, DIFFERENTIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; MYELITIS, TRANSVERSE; OPTIC NEURITIS; YOUNG ADULT;

EID: 84883139092     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072399     Document Type: Article

References (26)

1. Keegan BM, Noseworthy JH, (2002) Multiple sclerosis. Annu Rev Med 53: 285-302.
2. Compston A, Coles A, (2002) Multiple sclerosis. Lancet 359: 1221-1231.
3. Bielekova B, Martin R, (2004) Development of biomarkers in multiple sclerosis. Brain 127: 1463-1478.
4. Yuan X, Desiderio DM, (2005) Proteomics analysis of human cerebrospinal fluid. J Chromatogr B Analyt Technol Biomed Life Sci 815: 179-189.
5. Romeo MJ, Espina V, Lowenthal M, Espina BH, Petricoin EF 3rd, et al. (2005) CSF proteome: a protein repository for potential biomarker identification. Expert Rev Proteomics 2: 57-70.
6. Blennow K, Hampel H, (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613.
7. Giovannoni G, (2006) Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers 22: 187-196.
8. Gadient RA, Otten UH, (1997) Interleukin-6 (IL-6)-a molecule with both beneficial and destructive potentials. Prog Neurobiol 52: 379-390.
9. Pilcher H, (2005) Protein culprit found for transverse myelitis? Lancet Neurol 4: 702.
10. Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, et al. (2005) IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 115: 2731-2741.
11. Ishizu T, Minohara M, Ichiyama T, Kira R, Tanaka M, et al. (2006) CSF cytokine and chemokine profiles in acute disseminated encephalomyelitis. J Neuroimmunol 175: 52-58.
12. Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, et al. (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 256: 2082-2084.
13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302.
14. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846.
15. Krishnan C, Kaplin AI, Deshpande DM, Pardo CA, Kerr DA, (2004) Transverse Myelitis: pathogenesis, diagnosis and treatment. Front Biosci 9: 1483-1499.
16. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, et al. (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 62: 865-870.
17. Srivastava R, Aslam M, Kalluri SR, Schirmer L, Buck D, et al. (2012) Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 367: 115-123.
18. Akira S, Taga T, Kishimoto T, (1993) Interleukin-6 in biology and medicine. Adv Immunol 54: 1-78.
19. Houssiau FA, Bukasa K, Sindic CJ, Van Damme J, Van Snick J, (1988) Elevated levels of the 26K human hybridoma growth factor (interleukin 6) in cerebrospinal fluid of patients with acute infection of the central nervous system. Clin Exp Immunol 71: 320-323.
20. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J, (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 31: 784-788.
21. Swaak AJ, van Rooyen A, Aarden LA, (1989) Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int 8: 263-268.
22. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA, (1990) Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40: 1735-1739.
23. Maimone D, Gregory S, Arnason BG, Reder AT, (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32: 67-74.
24. Harris VK, Sadiq SA, (2009) Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making. Mol Diagn Ther 13: 225-244.
25. Maimone D, Guazzi GC, Annunziata P, (1997) IL-6 detection in multiple sclerosis brain. J Neurol Sci 146: 59-65.
26. Frei K, Fredrikson S, Fontana A, Link H, (1991) Interleukin-6 is elevated in plasma in multiple sclerosis. J Neuroimmunol 31: 147-153.